Icu Medical Inc/De (NASDAQ: ICUI)

$133.31 ▲ +2.18 (+1.66%)

As of May 22, 2026 04:00 PM

Sector: Healthcare Industry: Medical Instruments & Supplies CIK: 0000883984

Market Cap 3.25 Bn

P/E 70.12

P/S 1.51

Div. Yield 0.00

ROIC (Qtr) 0.00

Total Debt (Qtr) 1.28 Bn

Revenue Growth (1y) (Qtr) -12.32

Add ratio to table...

About

ICU Medical, Inc. develops manufactures and sells innovative medical products used in infusion therapy vascular access and vital care applications. Headquartered in San Clemente California the company was founded in 1984 and serves customers worldwide with a portfolio that includes infusion pumps safety software infusion sets needle free connectors catheters sharps safety devices tracheostomy tubes hemodynamic monitors anesthesia equipment temperature management devices and regional anesthesia kits. The company emphasizes quality innovation and...

ICU Medical, Inc. develops manufactures and sells innovative medical products used in infusion therapy vascular access and vital care applications. Headquartered in San Clemente California the company was founded in 1984 and serves customers worldwide with a portfolio that includes infusion pumps safety software infusion sets needle free connectors catheters sharps safety devices tracheostomy tubes hemodynamic monitors anesthesia equipment temperature management devices and regional anesthesia kits. The company emphasizes quality innovation and value in its efforts to support clinical caregivers and improve patient outcomes.

The company generates revenue primarily through the sale of its medical products to healthcare providers and distributors. Its consumables business contributes sales from infusion therapy products such as non dedicated infusion sets extension sets needle free connectors and disinfection caps oncology products like chemo lock and chemo clave vascular access items including peripheral IV catheters safety devices and tracheostomy tubes and kits. The infusion systems segment sells large volume pumps ambulatory infusion pumps syringe infusion pumps IV medication safety software and related professional services. The vital care segment derives revenue from the IV solutions business operated through a joint venture hemodynamic monitoring products general anesthesia and respiratory devices temperature management solutions and regional anesthesia and pain management products. Manufacturing takes place in facilities located in the United States Costa Rica Mexico and the Czech Republic. The company also relies on third party manufacturers for certain product lines while maintaining quality standards. Sales are conducted through a direct sales force and independent distributors reaching over one hundred countries worldwide.

The company operates through the following segments: Consumables Infusion Systems and Vital Care. Financial information for each segment is disclosed in the management discussion and analysis section of the annual report.

• The Consumables segment includes infusion therapy products such as non dedicated infusion sets extension sets needle free connectors and disinfection caps oncology offerings like chemo lock and chemo clave vascular access products such as peripheral IV catheters safety devices and tracheostomy tubes and kits. These products are designed to support safe and efficient delivery of fluids and medications while reducing the risk of infection and needlestick injury.

• The Infusion Systems segment provides large volume pumps ambulatory infusion pumps syringe infusion pumps IV medication safety software and professional services that assist customers with configuration implementation and data analytics. The software platforms integrate with hospital electronic health records to enhance medication management and workflow efficiency.

• The Vital Care segment encompasses the IV solutions business conducted via a joint venture hemodynamic monitoring systems general anesthesia and respiratory equipment temperature management solutions and regional anesthesia and pain management trays and kits. These offerings help clinicians monitor cardiac function deliver anesthesia regulate temperature and manage pain during surgical and critical care procedures.

ICU Medical, Inc. competes in the medical device industry with several large and specialized firms. In the consumables market its primary competitors are Becton Dickinson Baxter B Braun Angiodynamics Teleflex EquaShield and Medtronic. In the infusion systems market it faces competition from Becton Dickinson Baxter B Braun Moog Medical and Fresenius Kabi. In the vital care market rivals include Baxter B Braun Edwards Lifesciences Belmont Medical Technologies and Intersurgical. The company’s competitive advantages stem from its broad product portfolio that enables a one stop shop for customers its focus on innovation safety and quality and its extensive global distribution network. The firm’s diversified product mix allows it to cross sell complementary items and increase wallet share with existing accounts. Continued investment in research and development enables the introduction of new technologies that address evolving clinical needs.

The company’s customers consist mainly of acute care hospitals wholesalers ambulatory clinics and alternate site facilities such as outpatient clinics home health care providers and long term care centers. ICU Medical also sells its products through independent distributors who serve additional markets across more than one hundred countries. While specific customer names are not disclosed the firm notes that a single distributor accounted for approximately eighteen percent of its net sales in recent periods. The company reports that a single distributor contributed roughly eighteen percent of total sales in the last three fiscal years. No individual end user customer accounts for a material portion of revenue.

Investment thesis

Bull case

ICU Medical’s deconsolidation of IV Solutions after the Otsuka JV removed a significant cost base from the income statement, effectively creating a clean slate for margin expansion. The one‑time $4 million settlement from the Italian payback liability further nudged gross margin up, illustrating how strategic debt restructuring can translate into operating leverage. Over the past quarters, the company has consistently improved its operating expense profile, cutting incentive compensation and deferring discretionary spend, thereby boosting EBITDA without sacrificing sales growth. These actions demonstrate a disciplined approach to balance‑sheet management that can sustain profitability even in a volatile pricing environment.
The consumables division delivered an 8 % top‑line increase, driven by new global customer implementations and rapid growth in niche markets such as oncology and dialysis. This segment is poised for sustained expansion as it continues to roll out line extensions that add workflow efficiencies and safety features, aligning with clinicians’ demand for data‑driven infusion solutions. The 510(k) filings for the MedFusion 5000 syringe pump and CATA ambulatory pumps signal a future product pipeline that can capture new revenue streams once FDA clearance is obtained. Early discussions with key stakeholders suggest these devices will be integrated into the existing product ecosystem, enhancing cross‑sell opportunities.
IV Systems saw a 9 % revenue increase, underpinned by double‑digit growth in LVP pumps and dedicated sets. The company’s proactive engagement in RFP processes and the recent rollout of Plum Solo provide a clear renewal path for an already sizeable installed base. Even though the installation cadence is currently uneven, the strategic focus on refreshing older pumps indicates a long‑term revenue uplift from the existing customer portfolio. The anticipated multi‑year refresh cycle for Plum 360, combined with software and connectivity initiatives, is positioned to capture recurring revenue beyond the traditional pump life cycle.
The credit facility refinance, which increased Term Loan A by $190 million to retire higher‑rate Term Loan B, will lower annual interest expense by roughly $2 million. This move improves the company’s leverage ratio and positions it to reduce debt burden more aggressively over the next few years. By freeing up cash that would otherwise go to interest, ICU Medical can invest in R&D, marketing, and potential acquisitions, thereby accelerating growth and maintaining competitive advantage. A lower debt profile also provides a cushion against potential macro‑economic headwinds, such as currency fluctuations or supply‑chain disruptions.
Management’s stated aim to reach a 40‑45 % gross margin range reflects a realistic target that considers tariff impacts and integration synergies. The company has already closed the remaining two‑percentage‑point gap, and the ongoing operational improvements indicate that margin compression may be short‑lived. The firm’s commitment to continuous process optimization, including lean manufacturing and supply‑chain rationalization, will likely sustain or even exceed the target margin in the medium term. With the potential to leverage cost savings into higher pricing, the company could further improve profitability while maintaining market share.

ICU Medical’s deconsolidation of IV Solutions after the Otsuka JV removed a significant cost base from the income statement, effectively creating a clean slate for margin expansion. The one‑time $4 million settlement from the Italian payback liability further nudged gross margin up, illustrating how strategic debt restructuring can translate into operating leverage. Over the past quarters, the company has consistently improved its operating expense profile, cutting incentive compensation and deferring discretionary spend, thereby boosting EBITDA without sacrificing sales growth. These actions demonstrate a disciplined approach to balance‑sheet management that can sustain profitability even in a volatile pricing environment.
The consumables division delivered an 8 % top‑line increase, driven by new global customer implementations and rapid growth in niche markets such as oncology and dialysis. This segment is poised for sustained expansion as it continues to roll out line extensions that add workflow efficiencies and safety features, aligning with clinicians’ demand for data‑driven infusion solutions. The 510(k) filings for the MedFusion 5000 syringe pump and CATA ambulatory pumps signal a future product pipeline that can capture new revenue streams once FDA clearance is obtained. Early discussions with key stakeholders suggest these devices will be integrated into the existing product ecosystem, enhancing cross‑sell opportunities.
IV Systems saw a 9 % revenue increase, underpinned by double‑digit growth in LVP pumps and dedicated sets. The company’s proactive engagement in RFP processes and the recent rollout of Plum Solo provide a clear renewal path for an already sizeable installed base. Even though the installation cadence is currently uneven, the strategic focus on refreshing older pumps indicates a long‑term revenue uplift from the existing customer portfolio. The anticipated multi‑year refresh cycle for Plum 360, combined with software and connectivity initiatives, is positioned to capture recurring revenue beyond the traditional pump life cycle.
The credit facility refinance, which increased Term Loan A by $190 million to retire higher‑rate Term Loan B, will lower annual interest expense by roughly $2 million. This move improves the company’s leverage ratio and positions it to reduce debt burden more aggressively over the next few years. By freeing up cash that would otherwise go to interest, ICU Medical can invest in R&D, marketing, and potential acquisitions, thereby accelerating growth and maintaining competitive advantage. A lower debt profile also provides a cushion against potential macro‑economic headwinds, such as currency fluctuations or supply‑chain disruptions.
Management’s stated aim to reach a 40‑45 % gross margin range reflects a realistic target that considers tariff impacts and integration synergies. The company has already closed the remaining two‑percentage‑point gap, and the ongoing operational improvements indicate that margin compression may be short‑lived. The firm’s commitment to continuous process optimization, including lean manufacturing and supply‑chain rationalization, will likely sustain or even exceed the target margin in the medium term. With the potential to leverage cost savings into higher pricing, the company could further improve profitability while maintaining market share.

Bear case

Tariff exposure remains a significant uncertainty, and management’s evasive stance on the long‑term impact suggests potential margin erosion in the future. The company has repeatedly cautioned against annualizing current tariff effects, yet it has not provided a concrete mitigation strategy or contingency plan. Should tariff rates rise or trade tensions persist, ICU Medical could face higher input costs that are difficult to pass on to payers, especially in price‑sensitive markets. This scenario would compress the company’s already modest gross margin improvements and could derail the 40‑45 % target.
The Vital Care segment’s dramatic 52 % revenue decline underscores a broader weakness that management has yet to decisively address. The lack of a clear exit or pivot strategy signals that ICU Medical may be carrying a legacy business that does not align with its core infusion focus. Continued losses from this segment could drain resources, dilute earnings, and divert management attention from growth initiatives. Moreover, the segment’s performance may erode investor confidence in the company’s strategic direction.
Regulatory uncertainty remains a persistent risk, as evidenced by the ongoing FDA warning letters and the protracted approval process for the MedFusion 5000 and CADA ambulatory pumps. Management’s description of the FDA engagement as “business‑as‑usual” may downplay the real likelihood of delays or additional compliance costs. Any extended hold‑up could postpone revenue recognition for these critical products, stalling the company’s pipeline and exposing it to a competitive disadvantage. In the worst case, regulatory setbacks could trigger a re‑evaluation of the company’s risk profile by investors and credit rating agencies.
ICU Medical’s high debt load, totaling $1.3 billion, poses a risk if the company’s earnings trajectory falters. Although the recent refinancing reduced interest costs, the firm remains highly leveraged relative to its EBITDA. Rising interest rates or a deterioration in credit spreads could increase debt servicing obligations, squeezing free cash flow and limiting the capacity for future capital expenditures or share buybacks. This exposure is amplified by the company’s plan to potentially pursue further acquisitions or portfolio expansion, which would require additional financing under uncertain market conditions.
The company’s reliance on the installation and renewal cycle of the Plum 360 base creates a vulnerability to demand volatility. While management highlights an expected multi‑year refresh, the timeline for installations remains uncertain, and a slowdown in the adoption of new pumps could compress revenue growth. Moreover, any unforeseen technical issues or safety concerns with the Plum platform could erode market confidence and lead to costly recalls or product liability litigation. The resulting impact on cash flow and brand reputation could be significant.

Tariff exposure remains a significant uncertainty, and management’s evasive stance on the long‑term impact suggests potential margin erosion in the future. The company has repeatedly cautioned against annualizing current tariff effects, yet it has not provided a concrete mitigation strategy or contingency plan. Should tariff rates rise or trade tensions persist, ICU Medical could face higher input costs that are difficult to pass on to payers, especially in price‑sensitive markets. This scenario would compress the company’s already modest gross margin improvements and could derail the 40‑45 % target.
The Vital Care segment’s dramatic 52 % revenue decline underscores a broader weakness that management has yet to decisively address. The lack of a clear exit or pivot strategy signals that ICU Medical may be carrying a legacy business that does not align with its core infusion focus. Continued losses from this segment could drain resources, dilute earnings, and divert management attention from growth initiatives. Moreover, the segment’s performance may erode investor confidence in the company’s strategic direction.
Regulatory uncertainty remains a persistent risk, as evidenced by the ongoing FDA warning letters and the protracted approval process for the MedFusion 5000 and CADA ambulatory pumps. Management’s description of the FDA engagement as “business‑as‑usual” may downplay the real likelihood of delays or additional compliance costs. Any extended hold‑up could postpone revenue recognition for these critical products, stalling the company’s pipeline and exposing it to a competitive disadvantage. In the worst case, regulatory setbacks could trigger a re‑evaluation of the company’s risk profile by investors and credit rating agencies.
ICU Medical’s high debt load, totaling $1.3 billion, poses a risk if the company’s earnings trajectory falters. Although the recent refinancing reduced interest costs, the firm remains highly leveraged relative to its EBITDA. Rising interest rates or a deterioration in credit spreads could increase debt servicing obligations, squeezing free cash flow and limiting the capacity for future capital expenditures or share buybacks. This exposure is amplified by the company’s plan to potentially pursue further acquisitions or portfolio expansion, which would require additional financing under uncertain market conditions.
The company’s reliance on the installation and renewal cycle of the Plum 360 base creates a vulnerability to demand volatility. While management highlights an expected multi‑year refresh, the timeline for installations remains uncertain, and a slowdown in the adoption of new pumps could compress revenue growth. Moreover, any unforeseen technical issues or safety concerns with the Plum platform could erode market confidence and lead to costly recalls or product liability litigation. The resulting impact on cash flow and brand reputation could be significant.

Product and Service Breakdown of Revenue (2025)

Peer comparison

Companies in the Medical Instruments & Supplies

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ISRG	Intuitive Surgical Inc	156.17 Bn	52.64	14.76	-
2	BDX	Becton Dickinson & Co	41.51 Bn	29.74	1.94	17.28 Bn
3	RMD	Resmed Inc	30.43 Bn	20.13	5.50	0.26 Bn
4	WST	West Pharmaceutical Services Inc	22.78 Bn	42.07	7.07	0.20 Bn
5	SOLV	Solventum Corp	13.39 Bn	9.37	1.62	5.08 Bn
6	COO	Cooper Companies, Inc.	12.33 Bn	31.01	2.97	2.50 Bn
7	ALGN	Align Technology Inc	11.65 Bn	27.31	2.84	-
8	BAX	Baxter International Inc	9.81 Bn	-72.70	0.91	9.46 Bn

Research Tools

Developers

Icu Medical Inc/De (NASDAQ: ICUI)

About

Investment thesis

Bull case

Bear case

Product and Service Breakdown of Revenue (2025)

Peer comparison

Research Tools

Developers

Icu Medical Inc/De (NASDAQ: ICUI)

About

Investment thesis

Bull case

Bear case

Product and Service Breakdown of Revenue (2025)

Peer comparison

Create an account

Sign In

Reset Password